[go: up one dir, main page]

WO2004020599A3 - Hedgehog antagonists, methods and uses related thereto - Google Patents

Hedgehog antagonists, methods and uses related thereto Download PDF

Info

Publication number
WO2004020599A3
WO2004020599A3 PCT/US2003/027279 US0327279W WO2004020599A3 WO 2004020599 A3 WO2004020599 A3 WO 2004020599A3 US 0327279 W US0327279 W US 0327279W WO 2004020599 A3 WO2004020599 A3 WO 2004020599A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
hedgehog antagonists
uses related
hedgehog pathway
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/027279
Other languages
French (fr)
Other versions
WO2004020599A2 (en
Inventor
Henryk K Dudek
Irina Karavanov
Carmen Pepicelli
Lee Rubin
Karen Kotkow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curis Inc
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Priority to AU2003265853A priority Critical patent/AU2003265853A1/en
Publication of WO2004020599A2 publication Critical patent/WO2004020599A2/en
Anticipated expiration legal-status Critical
Publication of WO2004020599A3 publication Critical patent/WO2004020599A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present application is directed to compositions and methods for inhibiting angiogenesis and treating or preventing unwanted cell proliferation, including tumors, by inhibiting the hedgehog pathway, e.g., with an antagonist of the hedgehog pathway such as those disclosed herein.
PCT/US2003/027279 2002-08-29 2003-08-29 Hedgehog antagonists, methods and uses related thereto Ceased WO2004020599A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003265853A AU2003265853A1 (en) 2002-08-29 2003-08-29 Hedgehog antagonists, methods and uses related thereto

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40714502P 2002-08-29 2002-08-29
US60/407,145 2002-08-29

Publications (2)

Publication Number Publication Date
WO2004020599A2 WO2004020599A2 (en) 2004-03-11
WO2004020599A3 true WO2004020599A3 (en) 2006-12-28

Family

ID=31978427

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/027279 Ceased WO2004020599A2 (en) 2002-08-29 2003-08-29 Hedgehog antagonists, methods and uses related thereto

Country Status (2)

Country Link
AU (1) AU2003265853A1 (en)
WO (1) WO2004020599A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9290497B2 (en) 2011-01-10 2016-03-22 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9708247B2 (en) 2013-03-15 2017-07-18 The Regents Of The University Of California Modulators of the eIF2alpha pathway

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709454B2 (en) * 1997-06-20 2010-05-04 New York University Methods and compositions for inhibiting tumorigenesis
US7741298B2 (en) * 1997-06-20 2010-06-22 New York University Method and compositions for inhibiting tumorigenesis
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7671200B2 (en) 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
CA2475879A1 (en) 2002-02-15 2003-08-28 Cytokinetics, Inc. Synthesis of quinazolinones
US7214800B2 (en) 2002-05-09 2007-05-08 Cytokinetics, Inc. Compounds, compositions, and methods
KR20050036911A (en) 2002-05-09 2005-04-20 싸이토키네틱스, 인코포레이티드 Compounds, methods and compositions
JP2005536475A (en) 2002-05-23 2005-12-02 サイトキネティクス・インコーポレーテッド Compounds, compositions and methods
CA2489367A1 (en) 2002-06-14 2003-12-24 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004009036A2 (en) 2002-07-23 2004-01-29 Cytokinetics, Inc. Compounds compositions and methods
JP2006501306A (en) 2002-09-30 2006-01-12 サイトキネティクス・インコーポレーテッド Compounds, compositions and methods
EP1692112A4 (en) 2003-12-08 2008-09-24 Cytokinetics Inc Compounds, compositions, and methods
AU2005231692B2 (en) * 2004-03-26 2011-01-27 Curis, Inc. RNA interference modulators of Hedgehog signaling and uses thereof
US20090047282A1 (en) * 2005-03-25 2009-02-19 Hideaki Tojo Prophylactic/Therapeutic Agent for Cancer
EP2386539B1 (en) 2005-12-23 2016-07-20 Zealand Pharma A/S 4-Aminoproline derivatives useful as lysine mimetics
ES2558856T3 (en) 2006-12-21 2016-02-09 Zealand Pharma A/S Synthesis of pyrrolidine compounds
TWI433674B (en) 2006-12-28 2014-04-11 Infinity Discovery Inc Cyclopamine analogs
JP5639895B2 (en) 2007-12-27 2014-12-10 インフィニティ ファーマスーティカルズ、インク． Stereoselective reduction method
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CL2009000429A1 (en) 2008-02-26 2009-09-25 Takeda Pharmaceuticals Co Compounds derived from fused carbamoyl-heterocycles, especially pyrrolo [3,2-c] pyridine-2-carboxamides, smo inhibitors; pharmaceutical composition comprising said compounds; and use in the prophylaxis or treatment of cancer.
US20110217294A1 (en) * 2008-04-11 2011-09-08 Daniel Fults Combination of hgf inhibitor and hedgehog inhibitor to treat cancer
AU2009241561B2 (en) 2008-04-29 2013-05-16 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
HRP20130527T1 (en) 2008-11-03 2013-07-31 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
CN102216285B (en) 2008-11-17 2014-08-13 伊莱利利公司 Tetrasubstituted pyridazine hedgehog pathway antagonists
ES2446307T3 (en) 2008-11-17 2014-03-07 Eli Lilly And Company Tetrasubstituted pyridazines antagonists of the Hedgehog route
AR077014A1 (en) 2009-06-19 2011-07-27 Lilly Co Eli COMPOUND DERIVED FROM FTALAZINE 1,4-DISPOSED, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER
CA2769795C (en) 2009-08-05 2020-01-07 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
US8614208B2 (en) 2009-08-26 2013-12-24 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
WO2011024869A1 (en) 2009-08-26 2011-03-03 武田薬品工業株式会社 Fused heterocyclic ring derivative and use thereof
NZ598749A (en) 2009-08-26 2013-01-25 Takeda Pharmaceutical Fused heterocyclic ring derivative and use thereof
JP5722781B2 (en) 2009-08-26 2015-05-27 武田薬品工業株式会社 Fused heterocyclic derivatives and uses thereof
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
CA2817577A1 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2014000648A (en) 2011-07-19 2014-09-25 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof.
KR20140075693A (en) 2011-08-29 2014-06-19 인피니티 파마슈티칼스, 인코포레이티드 Heterocyclic compounds and uses thereof
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
HUE040126T2 (en) 2012-11-01 2019-02-28 Infinity Pharmaceuticals Inc Treatment of cancers using modulators of PI3 kinase isoform
US9844541B2 (en) 2012-11-29 2017-12-19 Strasspharma, Llc Methods of modulating follicle stimulating hormone activity
US20160024051A1 (en) 2013-03-15 2016-01-28 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
US20160113932A1 (en) 2013-05-30 2016-04-28 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX389256B (en) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc HETEROCYCLIC COMPOUNDS AND THEIR USES.
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN104906113A (en) * 2014-03-12 2015-09-16 淄博赛维医药技术有限公司 Antitumor medicine
WO2015143012A1 (en) 2014-03-19 2015-09-24 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX387917B (en) 2015-06-04 2025-03-19 Pellepharm Inc TOPICAL FORMULATIONS FOR DELIVERY OF HEDGEHOG INHIBITING COMPOUNDS AND THEIR USE.
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US20170231968A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
UA125216C2 (en) 2016-06-24 2022-02-02 Інфініті Фармасьютікалз, Інк. COMBINED THERAPY
DK3618847T3 (en) 2017-05-05 2021-05-25 Boston Medical Ct Corp GAP junction modulators of intercellular communication and their use in the treatment of diabetic eye disease
EP4229828A4 (en) 2020-10-13 2024-08-28 Endeavor Biomedicines, Inc. METHODS OF TREATING FIBROSIS
WO2025188802A1 (en) 2024-03-05 2025-09-12 Endeavor Biomedicines, Inc. Methods of improving lung function

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FUJITA E. ET AL.: "Involvement of Sonic Hedgehog in the Cell Growth of LK-2 cells, Human Lung Squamous Carcinoma Cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH, vol. 238, 1997, pages 658 - 664, XP003005586 *
MCGARVEY T.W. ET AL.: "PTCH gene mutations in invasive transitional cell carcinoma of the bladder", ONCOGENE, vol. 17, 1998, pages 1167 - 1172, XP003005585 *
TAIPALE J. ET AL.: "Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine", NATURE, vol. 406, 31 August 2000 (2000-08-31), pages 1005 - 1009, XP002166408 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9290497B2 (en) 2011-01-10 2016-03-22 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9708247B2 (en) 2013-03-15 2017-07-18 The Regents Of The University Of California Modulators of the eIF2alpha pathway
US10343981B2 (en) 2013-03-15 2019-07-09 The Regents Of The University Of California Modulators of the eIF2alpha pathway
US11220477B2 (en) 2013-03-15 2022-01-11 The Regents Of The University Of California Modulators of the eIF2alpha pathway

Also Published As

Publication number Publication date
WO2004020599A2 (en) 2004-03-11
AU2003265853A1 (en) 2004-03-19
AU2003265853A8 (en) 2004-03-19

Similar Documents

Publication Publication Date Title
WO2004020599A3 (en) Hedgehog antagonists, methods and uses related thereto
WO2002030462A3 (en) Hedgehog antagonists, methods and uses related thereto
WO2002032874A3 (en) Substituted heterocyclic compounds for treating multidrug resistance
WO2006071960A3 (en) Compositions and methods of treating cell proliferation disorders
WO2008064351A3 (en) (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
WO2005030791A3 (en) Isoquinolinone potassium channel inhibitors
WO2003074500A3 (en) N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors
HRP20020748A2 (en) Substituted beta-carbolines with ikb-kinase inhibiting activity
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
WO2002046171A3 (en) Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
WO2004098494A3 (en) Compounds, compositions, and methods
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
WO2004022537A3 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
WO2002096361A3 (en) 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
WO2009006389A8 (en) Pyrimidine derivatives useful as raf kinase inhibitors
WO2001071022A3 (en) Lpa receptor agonists and antagonists and methods of use
WO2007079164A3 (en) Protein kinase inhibitors
WO2005110994A8 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
WO2004032852A3 (en) Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
WO2005046578A3 (en) Isoquinolinone potassium channel inhibitors
PL1682530T3 (en) Pyrrole substituted indoles as inhibitors of pai-1
WO2005030130A3 (en) Isoquinoline potassium channel inhibitors
WO2005016883A3 (en) Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
WO2006034113A3 (en) Quinolone analogs as cell proliferation inhibitors
WO2004100890A3 (en) Rage g82s-related methods and compositions for treating inflammatory disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP